WO2025120560 - TARGETING MODULES AGAINST CD19 AND CD20 FOR USE IN A METHOD FOR STIMULATING A REVERSED
National phase entry is expected:
Publication Number
WO/2025/120560
Publication Date
12.06.2025
International Application No.
PCT/IB2024/062260
International Filing Date
05.12.2024
Title **
[English]
TARGETING MODULES AGAINST CD19 AND CD20 FOR USE IN A METHOD FOR STIMULATING A REVERSED
[French]
MODULES DE CIBLAGE CONTRE CD19 ET CD20 DESTINÉS À ÊTRE UTILISÉS DANS UN PROCÉDÉ DE STIMULATION D'UNE INVERSION
Applicants **
AVENCELL THERAPEUTICS INC.
Inventors
MEYER, Jan-Erik
SPEHR, Johannes
EHINGER, Armin
Priority Data
23215236.3
08.12.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2637 | |
| EPO | Filing, Examination, Granting | 12956 | |
| Japan | Filing, Examination, Granting | 2368 | |
| South Korea | Filing, Examination, Granting | 2412 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
25,313
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a targeting module comprising at least one CD19-binding domain, at least one CD20-binding domain and a tag or tag-binding domain, a pharmaceutical composition and a kit comprising the targeting module and a vector or a cell comprising a nucleotide sequence encoding a reversible chimeric antigen receptor[French]
La présente invention concerne un module de ciblage comprenant au moins un domaine de liaison CD19, au moins un domaine de liaison CD20 et un domaine de liaison à un marqueur ou un marqueur, une composition pharmaceutique et un kit comportant le module de ciblage et un vecteur ou une cellule comprenant une séquence nucléotidique codant pour un récepteur antigénique chimérique réversible.